Personalised Medicine
Your Genome Is Not Your Destiny — But It's a Surprisingly Good Map
For most of medical history, doctors treated the disease; personalised medicine proposes something more unsettling — treating the person who happens to have it.
The Idea
Standard medicine works on averages. A drug gets approved because it helped a statistically significant portion of a trial population, and then it gets prescribed to everyone who fits a broad diagnostic category. This is enormously useful and also, when you think about it, a little strange — because two people with 'the same' cancer can have tumours that are molecularly nothing alike. One will respond to a given chemotherapy agent; the other won't, and may suffer the side effects without any of the benefit. Personalised medicine — sometimes called precision medicine — flips this logic. Instead of asking 'what works for most people with this condition?', it asks 'what does this particular patient's biology tell us about what will work for them?' The key instrument is genomic sequencing: reading the specific mutations, gene expressions, and molecular signatures present in a patient's cells. But it also draws on proteomics (which proteins are being produced), metabolomics (the chemical fingerprints of cellular activity), and increasingly, the microbiome. What makes this genuinely new isn't just the technology — it's the shift in conceptual framework. Disease categories that looked clean and stable at the symptom level are fracturing into dozens of molecular subtypes. 'Breast cancer' is not one disease. 'Depression' may not be either. The diagnostic vocabulary medicine inherited from the 19th century is quietly being renegotiated at the level of the genome.
In the World
In 2011, a young woman named Emily Whitehead became the first child to receive a treatment called CAR-T cell therapy for acute lymphoblastic leukaemia — a cancer that had returned twice despite aggressive standard treatment. The approach was radically personalised: doctors extracted T-cells from her own immune system, genetically re-engineered them in a lab to recognise and attack her specific cancer cells, then infused them back into her body. She nearly died from the inflammatory response that followed. She survived. More than a decade later, she remains cancer-free. CAR-T is not a drug in the traditional sense. It cannot be manufactured in advance and stored on a shelf. It is built from the patient's own cells, customised to their disease, and it exists as a therapy only for that one person. The process costs a significant sum and takes weeks — constraints that make it inaccessible to most of the world right now. But it represents something important: proof that a therapy engineered around an individual's biology can succeed where population-average treatments have failed. Since Whitehead's case, the FDA has approved multiple CAR-T therapies. The pipeline of similar 'living drug' approaches — engineered to target specific mutations found through genomic sequencing — is now one of the most active areas in oncology. The question has shifted from 'is this possible?' to 'how do we make it scalable?'
Why It Matters
Most of us will navigate the healthcare system with the assumption that medicine knows, more or less, what it's doing when it prescribes a treatment. Personalised medicine complicates that comfort in a useful way. It suggests that a significant portion of why treatments fail — why antidepressants work brilliantly for one person and do nothing for another, why some people metabolise certain medications too quickly to benefit from them — is not mysterious bad luck but biological specificity that we simply hadn't learned to read yet. This changes how you might think about your own health decisions: asking a doctor not just 'what's the standard treatment?' but 'is there genomic or biomarker information that would tell us whether this treatment is likely to work for me specifically?' It also changes the ethical landscape. Who owns your genomic data? What does an insurer do with it? How do we ensure that therapies built for individual biology don't widen the gap between those who can access them and those who cannot? These aren't hypothetical concerns — they're already being contested in legislatures and courtrooms. Understanding what personalised medicine actually is makes you a more informed participant in those debates.
A Question to Ponder
If medicine increasingly has the tools to treat you as an individual rather than a statistical average, what responsibilities — to yourself, to your family who share your genome, to the healthcare system — does that create?
Get a new one of these every morning.
Start learning with Thinkable